Bristol Myers Squibb Cell Therapy Operations

Safety Insights for Bristol Myers Squibb Cell Therapy Operations

Bristol Myers Squibb Cell Therapy Operations operates an establishment with approximately 610 full-time equivalent workers in BOTHELL, WA, classified under the Gene therapy preparations manufacturing industry (NAICS 325414). Across 4 years of mandatory OSHA Injury Tracking Application (ITA) reporting, this employer has accumulated 10 recordable injuries, 12 occupational illnesses, and 0 workplace fatalities. The average Total Case Rate (TCR) of 0.9 injuries per 100 full-time workers per year provides the anchor metric for the A letter grade (Excellent Safety Record).

Benchmarked against the Bureau of Labor Statistics industry average of 3.3 for Gene therapy preparations manufacturing, Bristol Myers Squibb Cell Therapy Operations's workforce experiences 27% of the typical injury burden. This ratio matters because TCR already normalizes for hours worked — a 200,000-hour exposure base equals roughly 100 full-time workers — so establishments with very different headcounts can be compared directly. A TCR below the benchmark signals that controls, training, or automation may be outperforming peers.

Multi-year trend analysis is the single most reliable signal here: a one-year spike could reflect a single severe event, whereas sustained elevation across 4 reporting cycles points to systemic hazard exposure. Readers evaluating Bristol Myers Squibb Cell Therapy Operations as an employer, contractor, investment, or regulatory target should examine the yearly DART rate (days away, restricted, or transferred), the fatality count of 0, and any year-over-year deterioration shown in the table below. All figures come directly from employer-submitted OSHA Form 300A summaries — there is no modeling, estimation, or third-party adjustment layered on top of the government data.